Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:16 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,549 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcerative Clear all
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Nov 2, 2026, 2:16 AM EST
Completed Phase 2 Interventional

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

NCT00001165
View directory record Official record
Conditions
Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
Interventions
combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 2, 2026, 2:16 AM EST
Withdrawn Not applicable Interventional

Negative Pressure Wound Therapy as a Drug Delivery System (ADANPWT)

NCT02308800
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Quantum™ Therapy - NPWT with Prontosan, Quantum™ Therapy
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Nov 2, 2026, 2:16 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions

NCT00618228
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Balsalazide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 2, 2026, 2:16 AM EST
Completed Not applicable Interventional

Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers

NCT02880592
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Affinity Allograft, Standard of care
Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Miami Lakes, Florida • North Miami Beach, Florida • Clinton Township, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Nov 2, 2026, 2:16 AM EST
Terminated Not applicable Interventional Results available

Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses

NCT00663819
View directory record Official record
Conditions
Rectal Cancer, Ulcerative Colitis, Familial Adenomatous Polyposis, Diverticulitis
Interventions
GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement, Staple line without reinforcement
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
16
States / cities
Mobile, Alabama • Los Angeles, California • Weston, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Nov 2, 2026, 2:16 AM EST
Enrolling by invitation Not applicable Interventional

Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

NCT06560021
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Biopsy strategy
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
1,642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 2, 2026, 2:16 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

NCT03103412
View directory record Official record
Conditions
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
Interventions
TD-3504, 15N2-tofacitinib, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Nov 2, 2026, 2:16 AM EST
Completed Not applicable Interventional

DermACELL in Subjects With Chronic Wounds of the Lower Extremities

NCT01970163
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
DermACELL, GraftJacket, Conventional Care Dressings
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Montgomery, Alabama • Tucson, Arizona • Carlsbad, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Nov 2, 2026, 2:16 AM EST
Enrolling by invitation Phase 1 Interventional

Adipose-Derived Stromal Cells (ASC's) for Pressure Ulcers

NCT02375802
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Adipose-derived stromal cells, Adipose-derived stromal cells
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Nov 2, 2026, 2:16 AM EST
Completed Not applicable Interventional Results available

Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

NCT02294175
View directory record Official record
Conditions
Lower Extremity or Diabetic Foot Ulcers, Bacterial Infection
Interventions
Larval Debridement Therapy, Bedside Sharp Debridement
Device · Procedure
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Nov 2, 2026, 2:16 AM EST
Approved For Marketing No phase listed Expanded access

Zenith® TX2® Low Profile TAA Endovascular Graft

NCT02471781
View directory record Official record
Conditions
Aortic Aneurysm, Penetrating Ulcer, Vascular Disease
Interventions
Zenith TX2 Low Profile TAA Endovascular Graft
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 2, 2026, 2:16 AM EST
Completed No phase listed Observational

Clinical Trial to Examine Effectiveness of a Human Allograft for Treatment of DFU and VLU

NCT03999281
View directory record Official record
Conditions
Determine Effectiveness of Theraskin in the Treatment of DFU and VLU
Interventions
Human Allograft (Theraskin)
Other
Lead sponsor
Solsys Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Timeline
2003 – 2009
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Nov 2, 2026, 2:16 AM EST
Terminated Phase 2 Interventional Results available

Open-Label Study of Oral Treprostinil in Digital Ulcers

NCT00848107
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Nov 2, 2026, 2:16 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00321737
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
80
States / cities
Huntsville, Alabama • Tuscon, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Nov 2, 2026, 2:16 AM EST
Completed No phase listed Observational

Study of Subjects With Diabetic Foot Ulcer (DFU)

NCT03153007
View directory record Official record
Conditions
Diabetic Foot
Interventions
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Nov 2, 2026, 2:16 AM EST
Active, not recruiting Not applicable Interventional

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

NCT06811909
View directory record Official record
Conditions
Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Interventions
BR-AC, Standard Care
Other
Lead sponsor
BioStem Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Guntersville, Alabama • Castro Valley, California • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 2, 2026, 2:16 AM EST
Recruiting Not applicable Interventional

Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs

NCT06449638
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
Interventions
Standard of Care, Revita, Relese, Cogenex, Enverse
Other
Lead sponsor
StimLabs
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Omaha, Nebraska • Tulsa, Oklahoma • Jefferson Hills, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 2, 2026, 2:16 AM EST
Completed Not applicable Interventional Results available

Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds

NCT00971048
View directory record Official record
Conditions
Diabetic Foot Ulcers, Pressure Ulcers
Interventions
HP828-101, Hydrogel/Hydrocolloid
Device
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Bakersfield, California • Chula Vista, California • Fresno, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Nov 2, 2026, 2:16 AM EST
Completed Phase 3 Interventional Results available

The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis

NCT00620126
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
UC Home Automated Telemanagement, Best Available Care
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Nov 2, 2026, 2:16 AM EST
Recruiting Not applicable Interventional

Assessing Connected-Health, Pressure-Monitoring Technology for Improving Compression Therapy in Venous Leg Ulcer Treatment

NCT07152717
View directory record Official record
Conditions
Venous Leg Ulcers (VLUs)
Interventions
A connected-health, pressure-sensing system for monitoring sub-bandage pressure during compression therapy
Device
Lead sponsor
Feeltect Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 2, 2026, 2:16 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

NCT00616434
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
BG9418 (Interferon beta-1a), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Lakewood, Colorado • Bristol, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Nov 2, 2026, 2:16 AM EST
Completed No phase listed Observational

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

NCT02423512
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Nov 2, 2026, 2:16 AM EST
Terminated Phase 3 Interventional

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

NCT02318914
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Nov 2, 2026, 2:16 AM EST